ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma
In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels
These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway
VT3989...
ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after...
New computational method improves ability to detect precancerous tissues
CoCo-ST is a novel method of mapping tissues that is superior to current state-of-the-art benchmarks in preclinical models
Technique allows...
ASTRO 2025: At 10 years, SBRT comparable to surgery for early-stage lung cancer
Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small cell lung cancer
Survival outcomes were similar, but the SBRT group had fewer side effects and potentially less financial burden
Study further confirms radiation as an alternative for these patients, even in cases where the cancer is operable
Researchers from Â鶹ӳ» MD Anderson...
MD Anderson experts highlight top trends ahead of 2025 ASTRO meeting
Major themes include advances in actionable biomarkers in pancreatic cancer, proton therapy, artificial intelligence and theranostics
MD Anderson...
Researchers identify new approach to overcome resistance to KRAS-targeted therapies
Many cancers with KRAS mutations, the most commonly mutated oncogene, develop rapid resistance to targeted therapy with KRAS inhibitors. A...
Machine learning model improves treatment selection in non-small cell lung cancer
A significant challenge in developing treatment plans for patients with metastatic non-small cell lung cancer (NSCLC) is deciding whether...